PY314: Targeting Trem2 Positive Macrophages in Patients with Advanced Solid Tumors

Time: 9:00 am
day: Day One

Details:

• TREM2 is highly expressed on immune-suppressive TAMs within the TME, where it functions as a negative regulator of inflammatory responses
• Pionyr’s humanized IgG1 afucosylated monoclonal antibody (PY314) specifically binds human TREM2 and balances the TME (‘Myeloid Tuning’) by specifically depleting TREM2+ TAMs, via antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP)
• Preclinical and clinical results from a first in human trial of PY314 alone and in combination with pembrolizumab

Speakers: